These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 38764025

  • 1. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H, Du X, Liu W, Zhang C, Li Y, Hou J, Yu Y, Li G, Wang Q.
    Respir Res; 2024 May 20; 25(1):215. PubMed ID: 38764025
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun 20; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

  • 5. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B, Park YS, Sung JS, Lee JW, Lee SB, Kim YH.
    Cancer Med; 2021 Jan 20; 10(1):372-385. PubMed ID: 33314735
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J, You L, Yao J, Xie J, Jing J, Jing Z, Jiang L, Sui X, Pan H, Han W.
    Cancer Lett; 2016 Aug 28; 379(1):124-33. PubMed ID: 27264264
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis.
    Dai CH, Zhu LR, Wang Y, Tang XP, Du YJ, Chen YC, Li J.
    J Cell Physiol; 2021 Jun 28; 236(6):4538-4554. PubMed ID: 33230821
    [Abstract] [Full Text] [Related]

  • 13. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH, Shu Y, Chen P, Wu JN, Zhu LH, Yuan RX, Long WG, Zhu YM, Li J.
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec 28; 1864(12):3786-3798. PubMed ID: 30315932
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y, Zeng Y, Liu T, Du W, Zhu J, Liu Z, Huang JA.
    Respir Res; 2019 Jul 22; 20(1):164. PubMed ID: 31331328
    [Abstract] [Full Text] [Related]

  • 16. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z, Gao W.
    Arch Toxicol; 2019 Jun 22; 93(6):1555-1571. PubMed ID: 30993382
    [Abstract] [Full Text] [Related]

  • 17. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
    Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K.
    Cancer Lett; 2024 Aug 28; 598():217124. PubMed ID: 39059573
    [Abstract] [Full Text] [Related]

  • 18. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P, Xiang Y, Liu X, Zhang T, Yang R, Chen S, Xu L, Yu Q, Zhao H, Zhang L, Liu Y, Si Y.
    Molecules; 2019 Feb 12; 24(3):. PubMed ID: 30759826
    [Abstract] [Full Text] [Related]

  • 19. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y, Zang H, Qian G, Owonikoko TK, Ramalingam SR, Sun SY.
    Cancer; 2020 Mar 15; 126(6):1339-1350. PubMed ID: 31821539
    [Abstract] [Full Text] [Related]

  • 20. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.